Taro Pharmaceutical Industries Ltd. (TARO)

Market Cap	1.62B
Revenue (ttm)	629.18M
Net Income (ttm)	53.87M
Shares Out	37.58M
EPS (ttm)	1.43
PE Ratio	30.05
Forward PE	9.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	242,109
Open	42.97
Previous Close	42.97
Day's Range	42.89 - 42.98
52-Week Range	32.67 - 45.76
Beta	0.56
Analysts	Hold
Price Target	43.00 (+0.07%)
Earnings Date	Jul 24, 2024

About TARO

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1959
• Employees: 1,554
• Stock Exchange: NYSE
• Ticker Symbol: TARO

Financial Performance

In 2023, TARO's revenue was $629.18 million, an increase of 9.81% compared to the previous year's $572.95 million. Earnings were $53.87 million, an increase of 111.70%.

Analyst Forecast

According to one analyst, the rating for TARO stock is "Hold" and the 12-month stock price forecast is $43.0.

Price Target

$43.0

(0.07% upside)

Analyst Consensus: Hold